Your shopping cart is currently empty

BL-1249 is a selective and potent non-steroidal potassium channel activator with anti-inflammatory activity that activates K2P2.1 (TREK-1) and K2P10.1 (TREK-2).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $48 | In Stock | In Stock | |
| 5 mg | $113 | In Stock | In Stock | |
| 10 mg | $179 | In Stock | In Stock | |
| 25 mg | $272 | In Stock | In Stock | |
| 50 mg | $372 | In Stock | In Stock | |
| 100 mg | $653 | - | In Stock | |
| 500 mg | $1,350 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $157 | In Stock | In Stock |
| Description | BL-1249 is a selective and potent non-steroidal potassium channel activator with anti-inflammatory activity that activates K2P2.1 (TREK-1) and K2P10.1 (TREK-2). |
| Targets&IC50 | TREK2:8.0 μM (EC50), TREK1:5.5 μM (EC50), Smooth muscle cells (SMCs):21.0 μM (Human, EC50) |
| In vitro | Evaluated by a decrease in fluorescence of the voltage-sensitive dye bis(1,2-dibutylbarbituric acid)trimethine oxonol (EC50 = 1.26 +/- 0.6 μM) or direct electrophysiological measurements (EC50 = 1.49 +/- 0.08 μM), BL-1249 demonstrates concentration-dependent membrane depolarization in cultured human bladder smooth muscle cells[2]. Patch clamp experiments indicate that, akin to a diverse range of other TREK subfamily gating signals, BL-1249 stimulates a selective screening 'C-type' gate that controls K2P functionality. BL-1249 exhibits selectivity within the TREK subfamily, activating K2P2.1 (TREK-1) and K2P10.1 (TREK-2) approximately 10 times more actively than K2P4.1 (TRAAK). Studies on mutants and K2P2.1 (TREK-1)/K2P4.1 (TRAAK) chimeras highlight the critical role of the C-terminal tail in the action of BL-1249, and identify the M2/M3 transmembrane helix interface as a key site of BL-1249 selectivity[1]. |
| In vivo | In an anesthetized rat model, BL-1249 (1 mg/kg i.v.) decreased the number of isovolumic contractions, without significantly affecting blood pressure. Thus, BL-1249 behaves as a potassium channel activator that exhibits bladder versus vascular selectivity both in vitro and in vivo[2]. |
| Molecular Weight | 291.35 |
| Formula | C17H17N5 |
| Cas No. | 18200-13-0 |
| Smiles | C1CCc2c(C1)cccc2Nc1ccccc1-c1nnn[nH]1 |
| Relative Density. | 1.291g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 30 mg/mL (102.97 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.86 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.